MetaCap

Evaxion A/S (EVAX) vs Pelthos Therapeutics (PTHS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Evaxion A/S (EVAX) has outperformed Pelthos Therapeutics (PTHS) over the past year, losing 56.6% versus a loss of 74.9%. Pelthos Therapeutics is the larger company by market cap ($25.1 million vs $20.8 million), about 1.2 times the size. Evaxion A/S converts more of its revenue into profit, with a net margin of -102.4% versus -257.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVAX-56.56%PTHS-74.88%
+33%-23%-80%
Nov 21, 20251 yearNov 20, 2026
EVAX-88.89%PTHS-86.71%
+11%-44%-99%
Feb 12, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVAX versus PTHS key metrics
MetricEVAXPTHS
Share price$2.25$6.38
Market cap$20.75M$25.08M
1-day change+10.84%-8.73%
YTD return-52.83%-79.42%
1-year return-56.56%-74.88%
5-year return-99.07%—
EPS (TTM)$-1.00$-23.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.53M$16.80M
Revenue growth (YoY)+125.12%—
Net income (latest FY)$-7.71M$-43.32M
Gross margin—76.25%
Operating margin-122.66%-193.09%
Net margin-102.38%-257.93%
52-week high$6.92$31.62
52-week low$2.03$6.02
Distance from 52-week high-67.49%-79.82%
Analyst consensusnonestrong_buy
Avg. price target upside+400.00%+732.92%
Average volume85.00K54.38K
Shares outstanding9.22M3.93M
Employees4692
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EVAX has outperformed PTHS by 18.3 percentage points over the past year.
  • Evaxion A/S is more profitable, keeping -102.4 cents of every revenue dollar as net income versus -257.9 cents for Pelthos Therapeutics.

About Evaxion A/S

EVAX stock →

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees

About Pelthos Therapeutics

PTHS stock →

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees

EVAX vs PTHS FAQ

Which is bigger, Evaxion A/S or Pelthos Therapeutics?

Pelthos Therapeutics (PTHS) is larger, with a market capitalization of $25.08M compared with $20.75M for Evaxion A/S (EVAX).

Which stock has performed better over the past year, EVAX or PTHS?

EVAX returned -56.56% over the past 12 months, compared with -74.88% for PTHS (price return, excluding dividends). Past performance does not predict future results.

Are Evaxion A/S and Pelthos Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons